ArticleCancer medicine2021

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.

Hiroaki Kodama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.